Traditionally, anticoagulants used to treat signs and symptoms of VTE have included LMWH or vitamin K antagonists (VKAs).
LMWH has remained the standard treatment for cancer-associated VTE.
Most hospitalised patients with cancer and an acute medical condition require thromboprophylaxis throughout hospitalisation.
1, Patel, T. & Iglesias, D. A. Venous Thromboembolism Treatment and Prevention in Cancer Patients: Can We Use Pills Yet? Current Treatment Options in Oncology 2020;21:43
2. Ramacciotti, E. et al. Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019? Clinical and Applied Thrombosis/Hemostasis 2019;25
3. Treatment of Malignancy Associated Venous Thromboembolism - American College of Cardiology. Available at: https://www.acc.org/latest-in-cardiology/articles/2020/05/05/08/31/treatment-of-malignancy-associated-venous-thromboembolism (accessed 18 September 2020)
4. Lee, A. Y. Y. et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial. JAMA - J. Am. Med. Assoc. 2015;314:677–686
Developed by EPG Health for Medthority. This content has been developed independently of the sponsors who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.